News >

SOLO-1 Olaparib Trial Fosters Novel Applications of Frontline Maintenance in Ovarian Cancer

Caroline Seymour
Published: Friday, Jun 07, 2019

Mihaela C. Cristea, MD

Mihaela C. Cristea, MD

In the phase III SOLO-1 trial, olaparib (Lynparza) resulted in an unprecedented improvement in progression-free survival (PFS) as frontline maintenance therapy in women with BRCA-positive advanced ovarian cancer. With 2 additional PARP inhibitors under investigation, the field is likely to see survival improvements on the same scale in the future by homing in on a wider scope of aberrations, explained Mihaela C. Cristea, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication